MAS
56
-6
FFIV
67
-3
ALLE
37
-4
URI
49
-7
AMAT
40
-3
BRK.B
31
-2
CI
40
-5
LEG
31
-6
SE
58
-3
HOG
35
-3
PLD
46
-4
EW
41
5
PCAR
55
3
ZTS
54
-4
NWS
60
-2
ORLY
66
2
BMY
48
-3
PCG
58
-3
SYF
83
-5
MCK
55
-4
MAS
56
-6
FFIV
67
-3
ALLE
37
-4
URI
49
-7
AMAT
40
-3
BRK.B
31
-2
CI
40
-5
LEG
31
-6
SE
58
-3
HOG
35
-3
PLD
46
-4
EW
41
5
PCAR
55
3
ZTS
54
-4
NWS
60
-2
ORLY
66
2
BMY
48
-3
PCG
58
-3
SYF
83
-5
MCK
55
-4
Financhill
Back

Cosmo Pharmaceuticals NV Quote, Financials, Valuation and Earnings

Better Than Oil Stocks

CLICK HERE TO FIND OUT MORE
Sell
18

CMOPF
Cosmo Pharmaceuticals NV

Last Price:
69.62
Seasonality Move:
10.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)

Cosmo Pharmaceuticals NV Price Quote

$69.62

Cosmo Pharmaceuticals NV Key Stats

Sell
18
Cosmo Pharmaceuticals NV (CMOPF) is a Sell
Day range:
$69.62 - $69.62
52-week range:
$52.65 - $95.00
Dividend yield:
3.11%
P/E ratio:
0.00
P/S ratio:
5.62
P/B ratio:
2.09%
Volume:
0
Avg. volume:
1
1-year change:
42.81%
Market cap:
$1.1B
Revenue:
$100.4M
EPS:
$4.64

How Much Does Cosmo Pharmaceuticals NV Make?

Is Cosmo Pharmaceuticals NV Growing As A Company?

Data Unavailable

Cosmo Pharmaceuticals NV Stock Price Performance

What Is Cosmo Pharmaceuticals NV 52-Week High & Low?

Cosmo Pharmaceuticals NV Price To Free Cash Flow

Is It Risky To Buy Cosmo Pharmaceuticals NV?

Is Cosmo Pharmaceuticals NV Cash Flow Positive?

  • What Is CMOPF Cash Flow From Operations?
    Cash flow from operations (TTM) is $126.3M
  • What Is Cosmo Pharmaceuticals NV’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$204.2M
  • What Is Cosmo Pharmaceuticals NV’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $8.7M

Cosmo Pharmaceuticals NV Return On Invested Capital

  • Is Management Doing A Good Job?
    CMOPF return on invested capital is 13.36%
  • What Is Cosmo Pharmaceuticals NV Return On Assets?
    ROA measures how assets are converting to revenues and is 10.72%
  • What Is CMOPF Return On Equity?
    ROE is a measure of profitability and is 15.06%

Cosmo Pharmaceuticals NV Earnings Date & Stock Price

Cosmo Pharmaceuticals NV Competitors

Cosmo Pharmaceuticals NV Dividend Yield

Cosmo Pharmaceuticals NV Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many CMOPF shares are owned by institutional investors?
    2M CMOPF shares are owned by institutional investors
  • How many CMOPF shares are owned by insiders?
    0 CMOPF shares are owned by insiders